Veralox
is a California-based biotechnology company that researches and develops small-molecule therapeutics for the treatment of immuno-inflammatory diseases... Read moreVeralox
is a California-based biotechnology company that researches and develops small-molecule therapeutics for the treatment of immuno-inflammatory diseases... Read more
News
Dec 11, 2025
StreetInsider
Press Release: Veralox : Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Dec 11, 2025
Benzinga
Veralox: Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Jan 10, 2025
Citybizlist
Veralox: Veralox Therapeutics to Acquire Nudge Therapeutics
Aug 14, 2024
StreetInsider
Press Release: Veralox : Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
Jun 13, 2022
FirstWord Pharma
Veralox Therapeutics: Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
Jun 28, 2021
The Business Journals: Baltimore
Veralox Therapeutics: Frederick biotech readies for clinical trials armed with new executive, $17M in funding
Jan 26, 2021
MarketScreener
Veralox Therapeutics: Veralox Therapeutics : Announces FDA Orphan Drug Designation for VLX-1005
Jan 12, 2021
Baltimore Citybizlist
Veralox Therapeutics: Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Sep 11, 2019
Pulse2.0
Veralox Therapeutics: Veralox Secures $5.4 Million To Advance Development Of Therapeutics
Oct 18, 2018
PRWeb
Press Release: VERALOX Therapeutics : VERALOX Therapeutics and Frederick Innovative Technology Center, Inc. - Success Story
Veralox Competitors
1
2
3
4
5
6
7
8
9